Cambridge Medical Technologies (CMT)

A lab-on-a chip that reads blood biomarkers in interstitial fluid under the skin without puncturing it, then analyses it for diabetes, alcohol or drug abuse.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Rockville, MD, USA
  • Currency USD
  • Founded April 2014
  • Employees 15
  • Incorporation Type C-corp
  • Website cambridgemedtech.com

Company Summary

CMT was founded in 2014. We have raised investment of $8.5m to create a non-invasive patch which analyses blood biomarkers without puncturing the skin and without sensation for the user. Conditions we can monitor include sepsis, alcohol abuse and diabetes, for which we have robust trials data from Harvard Medical School's Joslin Centre. We have a manufacturing partnership in Japan, and R&D centres in Maryland and Cambridge, UK..

Team

  • Simon Harris
    Investment Adviser

    Simon has helped to found, fund and build series of technology ventures in the Medtech and Cleantech sectors. His first venture, a diabetes diagnostic system, is now part of a successful business listed on the London Stock Exchange.

  • Jack Jachmann
    CEO

    CEO Jack Jackmann knows how to turn technology into successful products. Previously he was head of R&D at Pitney Bowes, CEO of two of their subsidiary companies and CEO for Xerox, Cyalume and Zen Research. Chairman Michael Lacey-Solymar held senior roles at Investec and UBS and is NED at DrugDev Inc and Science Group plc.CFO James Cooke has held CFO positions for Fulham Inc, IdaTech Group plc, Dating Electronics Plc and Network Security Ltd.

  • Michael Lacey-Solymar
    Chairman

    Michael has had over 25 years’ experience within the financial industry, where he held several management positions with UBS and Investec.
    Michael was a Non-Executive Director of Chargemaster plc until its sale to BP in July 2018. Michael is a Non-Executive Director of Science Group plc and a partner in the Perfect Manors Partnership.
    In his role as chairman of CMT, Michael oversees board and investor relations.

  • James Cooke
    CFO

    James has over 20 years’ experience as a CFO, which has included CFO roles for Fulham Inc, IdaTech Group plc, Datong Electronics plc and Network Security Ltd. Since 1990, James has received significant global exposure as he has worked in the UK, Germany and USA.
    James joined CMT as a CFO where he oversees the financial management process, budgeting and forecasting.

  • Prof. John Currie
    Chief Scientist

    Prof. Currie is an inventor of several unique solid state micro system technologies for health monitoring and for drug delivery. One application is in the strict control of glucose concentrations and insulin injections in diabetics. The quantitative measurement paradigm requires the invention of new devices, made up of novel materials, fabricated using atomic and molecular deposition and patterning instruments and analyzed using adapted methods.

  • Alex Moseley
    Program Manager

    Alex is an authority on diabetes and a member of the Diagnostics Advisory Committee of the UK's national Institute of Clinical Excellence (NICE). She is leading a series of R&D programmes in the UK in partnership with the Universities of Cambridge, Manchester and Newcastle. Alex has a degree in International Finance from Wharton

Advisors

  • Dr Tito Bacarese-Hamilton
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free